Perfusion Scintigraphy in the Assessment of Autologous Cell Therapy in Diabetic Patients With Critical Limb Ischemia
Abstract
Perfusion scintigraphy with technetium-99-methoxy-isobutyl-isonitrile ((TC)-T-99m-MIBI) is often used for assessing myocardial function but the number of studies concerning lower limb perfusion is limited. The aim of our study was to assess whether (TC)-T-99m-MIBI was an eligible method for evaluation of the effect of cell therapy on critical limb ischemia (CLI) in diabetic patients. (TC)-T-99m-MIBI of calf muscles was performed before and 3 months after autologous cell therapy (ACT) in 24 diabetic patients with CLI.
Scintigraphic parameters such as rest count and exercising count after a stress test were defined. These parameters and their ratios were compared between treated and untreated (control) limbs and with changes in transcutaneous oxygen pressure (TcPO2) that served as a reference method.
The effect of ACT was confirmed by a significant increase in TcPO2 values (p<0.001) at 3 months after ACT. We did not observe any significant changes of scintigraphic parameters both at rest and after stress 3 months after ACT, there were no differences between treated and control limbs and no association with TcPO2 changes.
Results of our study showed no significant contribution of (TC)-T-99m-MIBI of calf muscles to the assessment of ACT in diabetic patients with CLI over a 3-month follow-up period.